Clofarabine

Generic Name
Clofarabine
Brand Names
Clolar, Evoltra
Drug Type
Small Molecule
Chemical Formula
C10H11ClFN5O3
CAS Number
123318-82-1
Unique Ingredient Identifier
762RDY0Y2H
Background

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...

Indication

For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.

Associated Conditions
Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
Associated Therapies
-
Clinical Trials
Related News

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2008-01-28
Last Posted Date
2018-03-09
Lead Sponsor
University of Washington
Target Recruit Count
50
Registration Number
NCT00602225
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

First Posted Date
2008-01-15
Last Posted Date
2014-09-12
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
7
Registration Number
NCT00593645
Locations
🇺🇸

Ravi Vij, M.D., St. Louis, Missouri, United States

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Leukemia
Interventions
Drug: clofarabine
Drug: gemtuzumab ozogamicin
First Posted Date
2007-12-20
Last Posted Date
2015-10-12
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
21
Registration Number
NCT00577694
Locations
🇺🇸

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

First Posted Date
2007-09-18
Last Posted Date
2022-03-24
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
38
Registration Number
NCT00531232
Locations
🇺🇸

Weill Medical College of Cornell University, New York, New York, United States

🇺🇸

Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

and more 3 locations

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

First Posted Date
2007-09-14
Last Posted Date
2016-03-24
Lead Sponsor
New York Medical College
Target Recruit Count
32
Registration Number
NCT00529360
Locations
🇺🇸

New York Medical College, Vallhala, New York, United States

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

First Posted Date
2007-07-19
Last Posted Date
2023-09-18
Lead Sponsor
University of Nebraska
Target Recruit Count
2
Registration Number
NCT00503880
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Cord Blood Expansion on Mesenchymal Stem Cells

First Posted Date
2007-07-10
Last Posted Date
2020-02-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
98
Registration Number
NCT00498316
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL

Phase 1
Completed
Conditions
Non Hodgkin's Lymphoma
First Posted Date
2007-05-24
Last Posted Date
2014-09-11
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
18
Registration Number
NCT00477945
Locations
🇺🇸

Indiana University Cancer Center, Indianapolis, Indiana, United States

A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT

Phase 1
Completed
Conditions
Hematologic Malignancies
First Posted Date
2007-05-23
Last Posted Date
2014-09-18
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
18
Registration Number
NCT00477542
Locations
🇺🇸

Indiana University Cancer Center, Indianapolis, Indiana, United States

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

First Posted Date
2007-05-04
Last Posted Date
2021-01-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
72
Registration Number
NCT00469014
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy